Sonus Pharmaceuticals of Bothell, WA, has received a positive opinion on its EchoGen ultrasound contrast agent from the Committee of Proprietary Medicinal Products, the scientific review committee of the European Medicines Evaluation Agency (EMEA). Sonus
Sonus Pharmaceuticals of Bothell, WA, has received a positive opinion on its EchoGen ultrasound contrast agent from the Committee of Proprietary Medicinal Products, the scientific review committee of the European Medicines Evaluation Agency (EMEA). Sonus expects the next regulatory step will be the issuance of a marketing authorization by the EMEA.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.